Roden headshot

Matthew Roden, Ph.D.

Executive Partner / Entrepreneur

Executive Partners

Cambridge Office

Dr. Matthew (Matt) Roden is an Entrepreneur at MPM and BioImpact Capital, an affiliate manager of MPM. He is the CEO of portfolio company Aktis Oncology. Matt also serves on the Boards of Directors of iTeos Therapeutics (NASDAQ: ITOS) and NextPoint Therapeutics, both portfolio companies, and is an investment committee member of the Oncology Impact Funds, private/public funds focused on oncology as well as new modalities, managed by BioImpact Capital.

Prior to joining MPM and BioImpact Capital, Matt’s career spanned senior leadership in large pharma, the healthcare equity capital markets, and in basic science as an immunologist and structural biologist. Most recently, Matt was Senior Vice President and Head of Enterprise Strategy at Bristol Myers Squibb. In this role, Matt delivered the initial strategic plan for the company following its acquisition of Celgene. Earlier, he served as Head of Strategic Corporate Development, accountable for mergers and acquisitions, structured transactions, strategic equity investing, and divestitures, and concurrently served as Head of Global BD Assessment, leading business development search and evaluation activities for all therapeutic categories. Matt served on the R&D Leadership Team representing external innovation and led teams on over 100 business development transactions that are cumulatively valued at over $125 billion, including Bristol Myers Squibb’s acquisition of Celgene, the largest acquisition in the healthcare industry to date.

Earlier, Matt was Head of Biotechnology Equity Research at UBS Investment Bank, he was a Senior Equity Analyst covering biotechnology at J.P. Morgan and Bank of America Merrill Lynch and was an Associate at Credit Suisse First Boston. In addition to his research coverage of the biotech sector, Matt and his teams provided equity research diligences and investor engagement on 24 equity offerings totaling $3.3bn in initial value from 2005-2016. Matt has also served in advisory or Board capacities to several organizations, including biotechnology companies, investment funds, BIO, BioNJ, and the State of New Jersey.

Matt earned a Ph.D. from the Albert Einstein College of Medicine, focusing on the structural biology of immune-relevant molecules. His graduate work was preceded by his pre-doctoral clinical research fellowship in immuno-oncology at the National Cancer Institute in Bethesda, Maryland. Matt holds a M.S. degree from Georgetown University and a B.S. from George Mason University.